AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-26. (canceled)

27. (currently amended) A method for the prevention or treatment of Alzheimer's disease (AD) in a subject having or suspected of having AD, comprising administering to said subject a therapeutically effective amount of an antibody wherein said antibody is raised against a protofibril comprising an Aβ-Arc peptide ~~comprising a mutation Glu$_{22}$-Gly$_{22}$~~ selected from the group consisting of Aβ39-Arc (Amino Acids 1-39 of SEQ ID NO:1), Aβ40-Arc (Amino Acids 1-40 of SEQ ID NO: 1), and Aβ42-Arc (SEQ ID NO: 1).

28-31. (canceled)

32. (previously presented) The method according to claim 27, wherein said antibody is monoclonal.

33. (previously presented) The method according to claim 27, wherein said antibody is human or humanized.

34-43. (canceled)

44. (previously presented) A method for the prevention or treatment of Alzheimer's disease (AD) in a subject having or suspected of having AD, comprising administering to said subject a therapeutically effective amount of an antibody, wherein said antibody is raised against a protofibril comprising an Aβ-Arc

peptide selected from the group consisting of Aβ39-Arc (Amino Acids 1-39 of SEQ ID NO:1), Aβ40-Arc (Amino Acids 1-40 of SEQ ID NO:1), Aβ41-Arc (Amino Acids 1-41 of SEQ ID NO:1), Aβ42-Arc (SEQ ID NO:1), and combinations thereof.

45. (previously presented) The method according to claim 44, wherein said protofibril further comprises an Aβ peptide having a mutation selected from the group consisting of the Dutch, Flemish, Italian, Iowa mutations, and combinations thereof.

46-47. (cancelled)

48. (previously presented) The method according to claim 27, wherein said protofibril further comprises an Aβ peptide with a mutation selected from the group consisting of the Dutch, Flemish, Italian and Iowa mutations.

49. (previously presented) The method according to claim 44, wherein said antibody is monoclonal.

50. (previously presented) The method according to claim 44, wherein said antibody is human or humanized.

51. (previously presented) A method for the prevention or treatment of Alzheimer's disease (AD) in a subject having or suspected of having AD, comprising administering to said subject a therapeutically effective amount of an antibody, wherein said antibody is raised against a composition comprising an Aβ-Arc peptide selected from the group consisting of Aβ39-Arc (Amino Acids 1-39 of SEQ ID NO:1), Aβ40-Arc (Amino Acids 1-40 of SEQ ID

3

NO:1), Aβ41-Arc (Amino Acids 1-41 of SEQ ID NO:1), Aβ42-Arc (SEQ
ID NO:1), and combinations thereof.

52. (currently amended) The method according to claim
44, wherein said ~~composition~~ protofibril further comprises an Aβ
peptide having a mutation selected from the group consisting of
the Dutch, Flemish, Italian, Iowa mutations, and combinations
thereof.

53. (previously presented) The method according to
claim 27, wherein said Aβ-Arc peptide is Aβ39-Arc (Amino Acids 1-
39 of SEQ ID NO:1).

54. (previously presented) The method according to
claim 27, wherein said Aβ-Arc peptide is Aβ40-Arc (Amino Acids 1-
40 of SEQ ID NO:1).

55. (previously presented) The method according to
claim 27, wherein said Aβ-Arc peptide is Aβ41-Arc (Amino Acids 1-
41 of SEQ ID NO:1).

56. (previously presented) The method according to
claim 27, wherein said Aβ-Arc peptide is Aβ42-Arc (SEQ ID NO:1).

57. (previously presented) The method according to
claim 44, wherein said Aβ-Arc peptide is Aβ39-Arc (Amino Acids 1-
39 of SEQ ID NO:1).

58. (previously presented) The method according to
claim 44, wherein said Aβ-Arc peptide is Aβ40-Arc (Amino Acids 1-
40 of SEQ ID NO:1).

59. (previously presented) The method according to claim 44, wherein said Aβ-Arc peptide is Aβ41-Arc (Amino Acids 1-41 of SEQ ID NO:1).

60. (previously presented) The method according to claim 44, wherein said Aβ-Arc peptide is Aβ42-Arc (SEQ ID NO:1).